BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38334069)

  • 21. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
    Zheng H; Chen ZS; Li J
    Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
    Le D; Konda B
    Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
    Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
    J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health plan budget impact analysis for pimecrolimus.
    Chang J; Sung J
    J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 29. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
    Baker CL; Ferrufino CP; Bruno M; Kowal S
    Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.
    Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial.
    Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM
    ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
    Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
    [No Abstract]   [Full Text] [Related]  

  • 34. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
    Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
    Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
    Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
    Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selpercatinib: First Approval.
    Markham A
    Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.